STAT+: Pharmalittle: J&J rivals rebuff bid to jointly study Covid-19 vaccine risks; will next-gen Covid shots be better or worse?
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to promenade with the official mascot, hang with our short person, catch up on some reading and attempt to beautify the Pharmalot grounds. And what about you? This may be a good time to do some spring cleaning around your castle. You could enjoy the great outdoors and get some exercise. You might also check on vaccination opportunities. Well, whatever you do, have a grand time. But be safe — wear mask. Enjoy, and see you soon …
Johnson & Johnson (JNJ) privately reached out to Covid-19 vaccine rivals to ask them to join an effort to study the risks of blood clots and speak with one voice about safety, but Pfizer (PFE) and Moderna (MRNA) declined, The Wall Street Journal reports. J&J also sought to build an informal alliance to communicate the benefits and risks of the shots and address public concerns about blood-clot cases. Pfizer and Moderna objected because they did not see a need to duplicate efforts of regulators and companies. One company was also concerned their shot could be tarnished by association. Only AstraZeneca agreed.
Continue to STAT+ to read the full story…
